XML 45 R33.htm IDEA: XBRL DOCUMENT
v3.24.0.1

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) | 9 Months Ended
--- | ---
Dec. 30, 2023
Segment Reporting [Abstract] |
Selected Information by Business Segment | Selected information by reportable segment is presented below:
| Three Months Ended |  | Nine Months Ended
(In thousands) | December 30, 2023 |  | December 31, 2022 |  | December 30, 2023 |  | December 31, 2022
Net revenues |  |  |  |  |  |  |
Plasma | $ | 146,718 |  |  | $ | 136,574 |  |  | $ | 426,948 |  |  | $ | 368,504 |
Blood Center | 71,615 |  |  | 76,827 |  |  | 207,833 |  |  | 219,052 |
Hospital | 113,794 |  |  | 93,889 |  |  | 316,688 |  |  | 275,635 |
Net revenues by business unit | 332,127 |  |  | 307,290 |  |  | 951,469 |  |  | 863,191 |
Service (1) | 5,586 |  |  | 5,372 |  |  | 16,395 |  |  | 15,918 |
Effect of exchange rates | (1,463) |  |  | (7,361) |  |  | (2,099) |  |  | (14,865) |
Net revenues | $ | 336,250 |  |  | $ | 305,301 |  |  | $ | 965,765 |  |  | $ | 864,244 |
(1) Reflects revenue for service, maintenance and parts |  |  |  |
| Three Months Ended |  | Nine Months Ended
(In thousands) | December 30, 2023 |  | December 31, 2022 |  | December 30, 2023 |  | December 31, 2022
Segment operating income |  |  |  |  |  |  |
Plasma | $ | 80,450 |  |  | $ | 76,365 |  |  | $ | 234,190 |  |  | $ | 203,098 |
Blood Center | 27,654 |  |  | 35,005 |  |  | 81,244 |  |  | 102,710 |
Hospital | 49,355 |  |  | 37,557 |  |  | 132,132 |  |  | 110,762 |
Segment operating income | 157,459 |  |  | 148,927 |  |  | 447,566 |  |  | 416,570 |
Corporate expenses (1) | (83,694) |  |  | (93,501) |  |  | (234,753) |  |  | (261,854) |
Effect of exchange rates | (401) |  |  | 3,581 |  |  | (879) |  |  | 9,775 |
Amortization of acquired intangible assets | (6,911) |  |  | (8,078) |  |  | (21,606) |  |  | (24,666) |
Integration and transaction costs | (4,869) |  |  | (287) |  |  | (7,768) |  |  | 425 |
Restructuring costs | (7,968) |  |  | (44) |  |  | (8,043) |  |  | (165) |
Restructuring related costs | (2,403) |  |  | (4,081) |  |  | (6,554) |  |  | (10,632) |
Digital transformation costs | (3,415) |  |  | — |  |  | (10,712) |  |  | — |
Impairment of assets and PCS2 related charges | (210) |  |  | 2 |  |  | (621) |  |  | 269 |
MDR and IVDR costs | (1,433) |  |  | (2,483) |  |  | (4,587) |  |  | (8,175) |
Litigation-related charges | (177) |  |  | (757) |  |  | (6,684) |  |  | (1,151) |
Impairment of intangible assets | — |  |  | — |  |  | (10,419) |  |  | — |
Gains on divestiture | — |  |  | — |  |  | — |  |  | 382 |
Operating income | $ | 45,978 |  |  | $ | 43,279 |  |  | $ | 134,940 |  |  | $ | 120,778 |
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Business Unit and Geographic Regions | Net revenues by business unit are as follows:
|  | Three Months Ended |  | Nine Months Ended
(In thousands) | December 30, 2023 |  | December 31, 2022 |  | December 30, 2023 |  | December 31, 2022
| Plasma | $ | 146,805 |  |  | $ | 135,461 |  |  | $ | 427,315 |  |  | $ | 365,735 |
| Apheresis | 50,666 |  |  | 52,398 |  |  | 151,380 |  |  | 152,287 |
| Whole Blood | 19,814 |  |  | 20,964 |  |  | 54,538 |  |  | 60,452 |
| Blood Center | 70,480 |  |  | 73,362 |  |  | 205,918 |  |  | 212,739 |
| Interventional Technologies(1) | 43,007 |  |  | 32,154 |  |  | 119,169 |  |  | 91,297 |
| Hemostasis Management | 41,423 |  |  | 34,921 |  |  | 116,241 |  |  | 102,737 |
| Other(2) | 28,989 |  |  | 24,485 |  |  | 80,760 |  |  | 76,875 |
| Hospital | 113,419 |  |  | 91,560 |  |  | 316,170 |  |  | 270,909 |
Net business unit revenues | 330,704 |  |  | 300,383 |  |  | 949,403 |  |  | 849,383 |
| Service | 5,546 |  |  | 4,918 |  |  | 16,362 |  |  | 14,861 |
Net revenues | $ | 336,250 |  |  | $ | 305,301 |  |  | $ | 965,765 |  |  | $ | 864,244 |
(1) Interventional Cardiology includes Vascular Closure and Sensor Guided Technologies product lines of the Hospital business unit.
(2) Other includes the Cell Salvage and Transfusion Management product lines of the Hospital business unit. |  |
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
| Three Months Ended |  | Nine Months Ended
(In thousands) | December 30, 2023 |  | December 31, 2022 |  | December 30, 2023 |  | December 31, 2022
United States | $ | 250,804 |  |  | $ | 224,104 |  |  | $ | 724,222 |  |  | $ | 617,824 |
Japan | 14,825 |  |  | 15,552 |  |  | 41,609 |  |  | 44,559 |
Europe | 37,035 |  |  | 39,105 |  |  | 115,088 |  |  | 121,412 |
Rest of Asia | 30,935 |  |  | 25,454 |  |  | 80,710 |  |  | 77,739 |
Other | 2,651 |  |  | 1,086 |  |  | 4,136 |  |  | 2,710 |
Net revenues | $ | 336,250 |  |  | $ | 305,301 |  |  | $ | 965,765 |  |  | $ | 864,244 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration